Daiichi's Pexidartinib: Potential Patient Impact Drives Advisory Cmte. Recommendation

 
• By Derrick Gingery

US FDA's ODAC members decide potential "life-changing" benefits of Daiichi's proposed rare cancer therapy outweigh liver risks.

More from US FDA Performance Tracker

More from Regulatory Trackers